So the EMERALD trial is a Phase III clinical trial in patients with ER-positive metastatic breast cancer, where patients were randomized to either receive an elacestrant which is an oral selective estrogen receptor down regulator or standard of care endocrine therapy, which was either an aromatase inhibitor or fulvestrant. The primary results in the trial were presented last year showing that elacestrant is superior to standard of care endocrine therapy...
So the EMERALD trial is a Phase III clinical trial in patients with ER-positive metastatic breast cancer, where patients were randomized to either receive an elacestrant which is an oral selective estrogen receptor down regulator or standard of care endocrine therapy, which was either an aromatase inhibitor or fulvestrant. The primary results in the trial were presented last year showing that elacestrant is superior to standard of care endocrine therapy. This year, we’re presenting results based on duration of CDK4/6 inhibitor prior to the enrollment of EMERALD and what we were able to show was that patients who had a longer duration of the CDK4/6 inhibitor had more benefit from an extended use of elacestrant.